Management of the neuropsychiatric and cognitive symptoms in Parkinson's disease

Practical Neurology

Volumn 2, Issue 2, 2002, Pages 94-102

  Hanagasi, Hasmet A ^a   Emre, Murat ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77952428870     PISSN: 14747758     EISSN: 14747766     Source Type: Journal    
DOI: 10.1046/j.1474-7766.2002.00404.x     Document Type: Article

References (25)

1. Ceravolo R, Nuti A, Piccini A et al. (2000) Paroxetine in Parkinson's disease: effects on motor and depressive symptoms. Neurology, 55, 1216-8.
2. Cummings JL (1992) Depression and Parkinson's disease. A Review. The American Journal of Psychiatry, 149, 443-54.
3. Cummings JL & Masterman DL (1999) Depression in patients with Parkinson's disease. International Journal of Geriatrics Psychiatry, 14, 711-8. (Pubitemid 29450282)
4. Dell'Agnello G, Ceravolo R, Nuti A et al. (2001) SSRIs do not worsen Parkinson's disease: Evidence from an open-label, prospective study. Clinical Neuropharmacology, 24, 221-7. (Pubitemid 32717856)
5. Douyon R, Serby M, Klutchko B & Rotrosen J (1989) ECT and Parkinson's disease revisited: 'a naturalistic' study. American Journal of Psychiatry, 146, 1451-5.
6. Friedman JH & Factor SA (2000) Atypical antipsychotics in the treatment of drug induced psychosis in Parkinson's disease. Movement Disorders, 15, 201-11. (Pubitemid 30167909)
7. Gimenez-Roldan S, Dobato JL & Mateo D (1997) Treatment of depression in Parkinson's disease with moclobemide: a pilot open-label study. Parkinsonism & Related Disorders, 30, 29-25.
8. Goetz CG, Blasucci LM, Leurgans S & Pappert EJ (2000) Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology, 55, 789-94.
9. Goetz CG, Tanner CM & Klawans HL (1984) Bupropion in Parkinson's disease. Neurology, 34, 1092-4. (Pubitemid 14094252)
10. Hutchinson M & Fazzini E (1996) Cholinesterase inhibition in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 61, 324-5/
11. Jansen Steur ENH (1993) Increase of Parkinson disability after fl uoxetine medication. Neurology, 43, 211-3.
12. Mayeux R, Stern Y, Cote C & Willams JB (1984) Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology, 34, 642-6 (Pubitemid 14143522)
13. McKeith I, Del Ser T, Spano PF et al. (2000) Effi cacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet, 9247, 2031-6. (Pubitemid 32009817)
14. McKeith IG, Galasko D, Kosaka K et al. (1996) Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB). Report of the consortium on DLB international workshop. Neurology, 47, 1113-24.
15. Meco G, Allesandri A, Bonifati V & Guistini P (1994) Risperidone for hallucinations in levodopa treated Parkinson's disease patients. Lancet, 343, 1370-1. (Pubitemid 24162601)
16. Parkinson Study Group (1999) Low dose clozapine for the treatment of drug-induced psychosis in idiopathic Parkinson's disease: Results of the double blind, placebo controlled PSYCLOPS trial. New England Journal of Medicine, 340, 757-63.
17. Paulus W & Jellinger K (1991) The neuropathologic basis of different clinical subgroups of Parkinson's disease. Journal of Neuropathology & Experimental Neurology, 50, 743-55.
18. Samuel W, Alford M, Hoffstetter CR & Hansen L (1997) Dementia with Lewy bodies versus pure Alzheimer disease: differences in cognition, neuropathology, cholinergic dysfunction, and synapse density. Journal of Neuropathology & Experimental Neurology, 56, 499-508. (Pubitemid 27463091)
19. Santamaria J, Tolosa E & Valles A (1986) Parkinson's disease with depression: a possible subgroup of idiopathic parkinsonism. Neurology, 36, 1130-3. (Pubitemid 16038602)
20. Shea C, MacKnight C & Rockwood K (1998) Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. International Psychogeriatrics, 10, 229-38. (Pubitemid 28470184)
21. The French Clozapine Parkinson Study Group (1999) Clozapine in drug-induced psychosis in Parkinson's disease. Lancet, 353, 2041-2.
22. Trosch RM, Freidman JH, Lannon MC et al. (1998) Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience. Movement Disorders, 13, 377-82. (Pubitemid 28221486)
23. Tröster AI, Paolo AM, Lyons KE, Glatt SL, Hubble JP & Koller WC (1995) The infl uence of depression on cognition in Parkinson's disease: a pattern of impairment distinguishable from Alzheimer's disease. Neurology, 45, 672-6.
24. Walsh K & Bennett G (2001) Parkinson's disease and anxiety. Postgraduate Medical Journal, 77, 89-93. (Pubitemid 32120976)
25. Zoldan J, Friedberg G, Livneh M & Melamed E (1995) Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT-3 receptor antagonist. Neurology, 45, 1305-8.